Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study (Q35179962)

7 August 2017

title

Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study (English)

1 reference

7 August 2017

main subject

cardiovascular disease

1 reference

11

Salim Yusuf

1 reference

7 August 2017

Jeffrey L Probstfield

5

object named as

Jeffrey Probstfield

1 reference

7 August 2017

Joshua I Barzilay

1

1 reference

7 August 2017

Peggy Gao

2

1 reference

7 August 2017

Lars Rydén

3

1 reference

7 August 2017

Helmut Schumacher

4

1 reference

7 August 2017

Patrick Commerford

6

1 reference

7 August 2017

Antonio Dans

7

1 reference

7 August 2017

Rafael Ferreira

8

1 reference

7 August 2017

Mátyás Keltai

9

1 reference

7 August 2017

Ernesto Paolasso

10

1 reference

7 August 2017

Koon Teo

12

1 reference

7 August 2017

TRANSCEND Investigators

13

1 reference

7 August 2017

language of work or name

English

0 references

publication date

25 July 2011

1 reference

7 August 2017

1 reference

7 August 2017

volume

34

1 reference

7 August 2017

issue

9

1 reference

7 August 2017

page(s)

1902-1907

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

7 August 2017

copyright license

start time

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Could mitochondrial efficiency explain the susceptibility to adiposity, metabolic syndrome, diabetes and cardiovascular diseases in South Asian populations?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

The cardiometabolic syndrome and sarcopenic obesity in older persons

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Effect of ramipril on the incidence of diabetes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

A European evidence-based guideline for the prevention of type 2 diabetes.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Effect of nateglinide on the incidence of diabetes and cardiovascular events

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Ramipril and the development of diabetes.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3161302

Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21788624

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC11-0545

1 reference

7 August 2017

1 reference

7 August 2017

1 reference